Syntaxin was founded in 2005 through a spinout of intellectual property and scientists from the Health Protection Agency , and benefits from 15 years of research in the field of bacterial toxin engineering. The company owns dominant patents and know-how in the design, manufacture and use of novel cell TSI engineered botulinum toxins. It has a strong IP base with over 40 granted patents for the platform and established products. Abingworth, Lundbeckfond Ventures, Seventure and SR One: It is a blue-chip investors, including supported..
Syntaxin targeted secretion inhibitors technology platformto provide Syntaxin TSI products are biological molecules in microbial cell culture, the selectively chosen on its target cells and internalized to endopeptidases in the cell cytoplasm synthesized preventing further vesicular secretion. A single dose provides a prolonged duration of weeks to months.Staff in this study are for research and development engineer Edward Light, assistant professor of pediatrics Salim Idriss, Prattville the undergraduate Kathryn Sullivan and associate professor of biomedical engineering playPatrick Wolf, all of Duke.